Positive Top-Line Phase 3 Data on Novel ADHD Treatment, CTx-1301

CONFERENCE REPORTER

Ann Childress, MD, the lead investigator in the phase 3 CTx-1301-022 study, discusses the positive data, recently shared at 2023 Psych Congress®. Data show that the novel treatment can last up to 16 hours, helpful for patients with long days.

Dr Childress is president of the Center for Psychiatry and Behavior Medicine, Inc, and adjunct associate professor at the University of Nevada Las Vegas School of Medicine and Touro University Nevada College of Osteopathic Medicine.

The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at Psych Congress®, an annual conference produced by HMP Global, LLC. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by HMP Global, LLC. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of HMP Global, LLC.